by Raynovich Rod | Feb 22, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
by Raynovich Rod | Feb 7, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 FEB 11, Momentum easing with some good stocks moves, XBI off 1.3% to $165.83. Coronavirus focus stocks are mixed with our holdings doing well. ABT up 1.24%, HOLX up 0.53% and Genmark Diagnostics (GNMK) up 33% to $22.46 on rumors of being acquired, but...
by Raynovich Rod | Jan 25, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
1/28/21 Update-2 VIR Hits $140 yesterday then rolls over to $58+ today! JPMorgan downgraded VIR letting some of the air out of the ballon. The recent speculation may have been about a VIR antibody mirroring the therapeutic potential of the Lilly (LLY) developments....
by Raynovich Rod | Jan 13, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Notes #1: Current Portfolio Positions Focus is Coronavirus diagnostics and vaccines. Gene therapy is poised for next wave: The Conference boosted many stocks as you might expect in a bull market for biotech. We reviewed rather quickly...
by Raynovich Rod | Jan 10, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Best Biotech Trades of 2020. We were on vacation over the past week and that combined with all the crazy mob news from the Capitol combined with the worsening pandemic makes it hard to focus . Nonetheless stocks are booming and many financial writers and analysts feel...
by Raynovich Rod | Nov 14, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/16 …Healthcare Stocks Underperform-Rotation or Head- Fake? Many of our picks are up over 10% in two weeks so it is not surprising that momentum has eased.However the market has pivoted over the past few days on the expectation of COVID vaccine...
by Raynovich Rod | Nov 8, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Macro
Healthcare Stocks Rally Huge-Over 5% in One Week Uncertainty over election whipsaws healthcare stocks. Market Likes Gridlock from election? Legislative action on drug pricing unlikely. Focus should be on fighting the Pandemic and passing a Stimulus package. Over a two...
by Raynovich Rod | Nov 1, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 11/4/20…Huge rally in Biotech and Healthcare -Call it the gridlock rally. Biotech Green Wave? As we picked them on Sunday evening the large cap biotech and healthcare stocks soared. Looks like the big stimulus trade has waned hurting industrials and...
by Raynovich Rod | Oct 25, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update-3 10/29. 1p EDT…Earnings reports stabilize biopharma stocks. Vaccine stocks strong. Gilead Sciences (GILD) beats but lowers guidance.Needs clinical news on deals. Stock lower. Amgen (AMGN) holds $216 after beat, osteoporosis drug opportunity. Early...
by Raynovich Rod | Oct 19, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-3 10/21 11a EDT Another day with a brisk sell-off in momentum stocks. Coronavirus plays hit hard: BNTX, QDEL, NVAX, OSUR etc. Is this sentiment shift from lack of stimulus or just election anxiety? After the close: CRISPR Therapeutics (CRSP) down 12.95% to...